• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Portal hypertension as immune mediate disease.门静脉高压作为免疫介导性疾病。
Hepat Mon. 2014 Jun 7;14(6):e18625. doi: 10.5812/hepatmon.18625. eCollection 2014 Jun.
2
Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".儿童非酒精性脂肪性肝病/非酒精性脂肪性肝炎:内分泌代谢“编程异常”
Hepat Mon. 2014 May 1;14(5):e17641. doi: 10.5812/hepatmon.17641. eCollection 2014 May.
3
Mechanisms of adaptation of the hepatic vasculature to the deteriorating conditions of blood circulation in liver cirrhosis.肝硬化时肝血管系统适应血液循环恶化状况的机制
World J Hepatol. 2016 Jun 8;8(16):665-72. doi: 10.4254/wjh.v8.i16.665.
4
Nodular regenerative hyperplasia: evolving concepts on underdiagnosed cause of portal hypertension.结节性再生性增生:被低估的门静脉高压症病因。
World J Gastroenterol. 2011 Mar 21;17(11):1400-9. doi: 10.3748/wjg.v17.i11.1400.
5
Antiangiogenic therapy for portal hypertension in liver cirrhosis: Current progress and perspectives.肝硬化门静脉高压症的抗血管生成治疗:现状与展望。
World J Gastroenterol. 2018 Sep 7;24(33):3738-3748. doi: 10.3748/wjg.v24.i33.3738.
6
Pathophysiology and a Rational Basis of Therapy.病理生理学与治疗的合理依据。
Dig Dis. 2015;33(4):508-14. doi: 10.1159/000374099. Epub 2015 Jul 6.
7
New cellular and molecular targets for the treatment of portal hypertension.治疗门静脉高压症的新细胞和分子靶点。
Hepatol Int. 2015 Apr;9(2):183-91. doi: 10.1007/s12072-015-9613-5. Epub 2015 Mar 5.
8
Clinicopathological features of nine cases of non-cirrhotic portal hypertension: current definitions and criteria are inadequate.9例非肝硬化性门静脉高压症的临床病理特征:现行定义和标准并不充分。
Histopathology. 2003 Mar;42(3):251-64. doi: 10.1046/j.1365-2559.2003.01586.x.
9
Liver cirrhosis.肝硬化。
Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):281-90. doi: 10.1016/j.bpg.2011.02.009.
10
Liver fibrosis: a dynamic and potentially reversible process.肝纤维化:一种动态且具有潜在可逆性的过程。
Histol Histopathol. 2010 Aug;25(8):1075-91. doi: 10.14670/HH-25.1075.

引用本文的文献

1
Nonresponse to intramuscular vaccination: An unmet need in hepatitis B vaccination.对肌内注射疫苗无反应:乙肝疫苗接种中未满足的需求。
Saudi J Gastroenterol. 2020 Oct 19;26(6):287-9. doi: 10.4103/sjg.SJG_472_20.
2
The role of inhalational anesthetic drugs in patients with hepatic dysfunction: a review article.吸入性麻醉药物在肝功能不全患者中的作用:一篇综述文章。
Anesth Pain Med. 2015 Jan 7;5(1):e23409. doi: 10.5812/aapm.23409. eCollection 2015 Feb.
3
Role of the diet as a link between oxidative stress and liver diseases.饮食作为氧化应激与肝脏疾病之间联系的作用。
World J Gastroenterol. 2015 Jan 14;21(2):384-95. doi: 10.3748/wjg.v21.i2.384.
4
Oxidative stress in obesity: a critical component in human diseases.肥胖中的氧化应激:人类疾病的关键组成部分。
Int J Mol Sci. 2014 Dec 26;16(1):378-400. doi: 10.3390/ijms16010378.

本文引用的文献

1
Etiology of Portal Hypertension in Children:A Single Center's Experiences.儿童门静脉高压症的病因:单中心经验
Middle East J Dig Dis. 2012 Oct;4(4):206-10.
2
Novel role of nuclear receptor Rev-erbα in hepatic stellate cell activation: potential therapeutic target for liver injury.核受体 Rev-erbα 在肝星状细胞活化中的新作用:肝损伤的潜在治疗靶点。
Hepatology. 2014 Jun;59(6):2383-96. doi: 10.1002/hep.27049. Epub 2014 Apr 29.
3
Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension.可溶性肿瘤坏死因子-α受体 I 是 TIPS 治疗肝硬化和门静脉高压患者的预后标志物。
PLoS One. 2013 Dec 26;8(12):e83341. doi: 10.1371/journal.pone.0083341. eCollection 2013.
4
Splanchnic-aortic inflammatory axis in experimental portal hypertension.实验性门静脉高压症内脏-主动脉炎症轴。
World J Gastroenterol. 2013 Nov 28;19(44):7992-9. doi: 10.3748/wjg.v19.i44.7992.
5
Novel inflammatory biomarkers of portal pressure in compensated cirrhosis patients.代偿期肝硬化患者门静脉压力的新型炎症生物标志物。
Hepatology. 2014 Mar;59(3):1052-9. doi: 10.1002/hep.26755. Epub 2014 Jan 29.
6
Novel serological neo-epitope markers of extracellular matrix proteins for the detection of portal hypertension.用于检测门静脉高压症的细胞外基质蛋白新型血清学新表位标志物。
Aliment Pharmacol Ther. 2013 Nov;38(9):1086-96. doi: 10.1111/apt.12484. Epub 2013 Sep 15.
7
Thyroid dysfunction in thalassaemic patients: ferritin as a prognostic marker and combined iron chelators as an ideal therapy.地中海贫血患者的甲状腺功能障碍:铁蛋白作为预后标志物和联合铁螯合剂作为理想的治疗方法。
Eur J Endocrinol. 2013 Oct 21;169(6):785-93. doi: 10.1530/EJE-13-0627. Print 2013 Dec.
8
Antioxidant properties of glutamine and its role in VEGF-Akt pathways in portal hypertension gastropathy.谷氨酰胺的抗氧化特性及其在门静脉高压性胃病血管内皮生长因子-Akt 通路中的作用。
World J Gastroenterol. 2013 Jul 28;19(28):4464-74. doi: 10.3748/wjg.v19.i28.4464.
9
Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis.瘦素受体阻断可降低实验性大鼠肝硬化模型的肝内血管阻力和门静脉压力。
Am J Physiol Gastrointest Liver Physiol. 2013 Oct 1;305(7):G496-502. doi: 10.1152/ajpgi.00336.2012. Epub 2013 Jul 25.
10
Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo.松弛素调节人源和鼠源肝星状细胞功能并改善体内门脉高压。
Hepatology. 2014 Apr;59(4):1492-504. doi: 10.1002/hep.26627. Epub 2014 Mar 3.

门静脉高压作为免疫介导性疾病。

Portal hypertension as immune mediate disease.

作者信息

Manti Sara, Marseglia Lucia, D'Angelo Gabriella, Filippelli Martina, Cuppari Caterina, Gitto Eloisa, Romano Claudio, Arrigo Teresa, Salpietro Carmelo

机构信息

Department of Pediatric Sciences, Genetics and Pediatric Immunology Unit, University of Messina, Messina, Italy.

出版信息

Hepat Mon. 2014 Jun 7;14(6):e18625. doi: 10.5812/hepatmon.18625. eCollection 2014 Jun.

DOI:10.5812/hepatmon.18625
PMID:24976841
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4071352/
Abstract

CONTEXT

Portal Hypertension (PH) is a progressive complication due to chronic liver disease. In addition to pathophysiologic changes in the micro-circulation, in PH are established fibrous tissue (periportal fibrous septal) and regenerative hyperplastic nodules (from micro- to macro-nodules) promoting hepatic architectural distortion.

EVIDENCE ACQUISITION

A literature search of electronic databases was undertaken for the major studies published from 1981 to today. The databases searched were: PubMed, EMBASE, Orphanet, Midline and Cochrane Library. We used the keywords: "portal hypertension, children, immune system, endocrine system, liver fibrosis".

RESULTS

It is believed that PH results from three "phenotype": ischemia-reperfusion, involving nervous system (NS); edema and oxidative damage, involving immune system; inflammation and angiogenesis, involving endocrine system. However, its exact cause still underdiagnosed and unknown.

CONCLUSIONS

PH is a dynamic and potentially reversible process. Researchers have tried to demonstrate mechanisms underlying PH and its related-complications. This review focuses on the current knowledge regarding the pathogenesis, and immune, endocrine-metabolic factors of disease. The strong positive association between immune system and development of PH could be efficient to identify non-invasive markers of disease, to modify prognosis of PH, and to development and application of specific and individual anti-inflammatory therapy.

摘要

背景

门静脉高压(PH)是慢性肝病导致的一种进行性并发症。除了微循环的病理生理变化外,PH还会形成促进肝脏结构扭曲的纤维组织(门静脉周围纤维间隔)和再生性增生结节(从微结节到巨结节)。

证据获取

对1981年至今发表的主要研究进行了电子数据库文献检索。检索的数据库有:PubMed、EMBASE、Orphanet、Midline和Cochrane图书馆。我们使用的关键词为:“门静脉高压、儿童、免疫系统、内分泌系统、肝纤维化”。

结果

人们认为PH由三种“表型”引起:缺血-再灌注,涉及神经系统(NS);水肿和氧化损伤,涉及免疫系统;炎症和血管生成,涉及内分泌系统。然而,其确切病因仍诊断不足且未知。

结论

PH是一个动态且可能可逆的过程。研究人员试图阐明PH及其相关并发症的潜在机制。本综述重点关注有关该疾病发病机制以及免疫、内分泌代谢因素的当前知识。免疫系统与PH发展之间的强正相关关系可能有助于识别疾病的非侵入性标志物、改善PH的预后以及开发和应用特定的个体化抗炎治疗。